Base de dados : MEDLINE
Pesquisa : D03.132.327.412.400 [Categoria DeCS]
Referências encontradas : 1861 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 187 ir para página                         

  1 / 1861 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27654501
[Au] Autor:Sran HK; Vathsala A
[Ad] Endereço:From the Division of Nephrology, Department of Medicine, National University Health System, 1E Kent Ridge Road, 119228, Singapore hersharan_kaur_sran@nuhs.edu.sg.
[Ti] Título:Renal infarction due to ergotamine.
[So] Source:QJM;109(11):749-750, 2016 Nov.
[Is] ISSN:1460-2393
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Ergotamina/efeitos adversos
Infarto/induzido quimicamente
Rim/irrigação sanguínea
Vasoconstritores/efeitos adversos
[Mh] Termos MeSH secundário: Ergotamina/uso terapêutico
Seres Humanos
Infarto/diagnóstico por imagem
Rim/diagnóstico por imagem
Masculino
Meia-Idade
Transtornos de Enxaqueca/tratamento farmacológico
Medicamentos sem Prescrição/efeitos adversos
Medicamentos sem Prescrição/uso terapêutico
Tomografia Computadorizada por Raios X
Vasoconstritores/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Nonprescription Drugs); 0 (Vasoconstrictor Agents); PR834Q503T (Ergotamine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170313
[Lr] Data última revisão:
170313
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160923
[St] Status:MEDLINE


  2 / 1861 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27624901
[Au] Autor:Amundsen S; Øvrebø TG; Amble NM; Poole AC; Nordeng H
[Ad] Endereço:Department of Laboratory Medicine, Division of Diagnostic Services, University Hospital of North Norway, PO Box 63, N-9038, Tromsø, Norway. siri.amundsen@unn.no.
[Ti] Título:Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women.
[So] Source:Eur J Clin Pharmacol;72(12):1525-1535, 2016 Dec.
[Is] ISSN:1432-1041
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Migraine is highly prevalent among women of fertile age. The main objectives of this study were to describe the prevalence and patterns of use of antimigraine medications during pregnancy and breastfeeding and to identify maternal and migraine-related factors associated with medication use during pregnancy. METHODS: The study is a cross-sectional internet-based survey among pregnant women and new mothers with migraine conducted in Norway from October 1, 2013 to February 1, 2014. Descriptive statistics were used to explore patterns of medication use, and logistic regression analysis was performed to examine the association between maternal socio-demographic and migraine-related factors and use of antimigraine medications during pregnancy. RESULTS: Of the total 401 respondents, 34.9 % were pregnant and 65.1 % had delivered within the last 18 months. The majority reported use of antimigraine medications during pregnancy (73.3 %) and postpartum (64.8 %), yet less than a third considered their migraine to be optimally treated during pregnancy (31.7 %) and the breastfeeding period (27.2 %). The patterns of medication use markedly changed during pregnancy and postpartum. Women with moderate or severe migraine were more likely to use antimigraine medications during pregnancy compared to women with mild migraine. CONCLUSIONS: Despite the fact that antimigraine medications were commonly used, the majority of the women felt that their migraine was suboptimally treated during pregnancy and postpartum. There was a decline in the use of medicines in pregnancy and postpartum, and the patterns of use markedly changed. Efforts to improve treatment of women with migraine during pregnancy and breastfeeding should be undertaken.
[Mh] Termos MeSH primário: Uso de Medicamentos/estatística & dados numéricos
Transtornos de Enxaqueca/tratamento farmacológico
Educação de Pacientes como Assunto
[Mh] Termos MeSH secundário: Adolescente
Adulto
Analgésicos/uso terapêutico
Anti-Inflamatórios não Esteroides/uso terapêutico
Aleitamento Materno
Estudos Transversais
Ergotamina/uso terapêutico
Feminino
Seres Humanos
Metoclopramida/uso terapêutico
Meia-Idade
Noruega/epidemiologia
Período Pós-Parto
Gravidez
Inquéritos e Questionários
Triptaminas/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Tryptamines); L4YEB44I46 (Metoclopramide); PR834Q503T (Ergotamine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160915
[St] Status:MEDLINE


  3 / 1861 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27068146
[Au] Autor:Vidal-Cantú GC; Jiménez-Hernández M; Rocha-González HI; Villalón CM; Granados-Soto V; Muñoz-Islas E
[Ad] Endereço:Laboratories of Neurobiology of Pain and Cardiovascular Pharmacology, Departamento de Farmacobiología, Cinvestav, Sede Sur, México D.F., México.
[Ti] Título:Role of 5-HT5A and 5-HT1B/1D receptors in the antinociception produced by ergotamine and valerenic acid in the rat formalin test.
[So] Source:Eur J Pharmacol;781:109-16, 2016 Jun 15.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Sumatriptan, dihydroergotamine and methysergide inhibit 1% formalin-induced nociception by activation of peripheral 5-HT1B/1D receptors. This study set out to investigate the pharmacological profile of the antinociception produced by intrathecal and intraplantar administration of ergotamine (a 5-HT1B/1D and 5-HT5A/5B receptor agonist) and valerenic acid (a partial agonist at 5-HT5A receptors). Intraplantar injection of 1% formalin in the right hind paw resulted in spontaneous flinching behavior of the injected hindpaw of female Wistar rats. Intrathecal ergotamine (15nmol) or valerenic acid (1 nmol) blocked in a dose dependent manner formalin-induced nociception. The antinociception by intrathecal ergotamine (15nmol) or valerenic acid (1nmol) was partly or completely blocked by intrathecal administration of the antagonists: (i) methiothepin (non-selective 5-HT5A/5B; 0.01-0.1nmol); (ii) SB-699551 (selective 5-HT5A; up to 10nmol); (iii) anti-5-HT5A antibody; (iv) SB-224289 (selective 5-HT1B; 0.1-1nmol); or (v) BRL-15572 (selective 5-HT1D; 0.1-1nmol). Likewise, antinociception by intraplantar ergotamine (15nmol) and valerenic acid (10nmol) was: (i) partially blocked by methiothepin (1nmol), SB-699551 (10nmol) or SB-224289 (1nmol); and (ii) abolished by BRL-15572 (1nmol). The above doses of antagonists (which did not affect per se the formalin-induced nociception) were high enough to completely block their respective receptors. Our results suggest that ergotamine and valerenic acid produce antinociception via 5-HT5A and 5-HT1B/1D receptors located at both spinal and peripheral sites. This provides new evidence for understanding the modulation of nociceptive pathways in inflammatory pain.
[Mh] Termos MeSH primário: Analgésicos/farmacologia
Ergotamina/farmacologia
Formaldeído/efeitos adversos
Indenos/farmacologia
Receptor 5-HT1A de Serotonina/metabolismo
Receptor 5-HT1B de Serotonina/metabolismo
Receptor 5-HT1D de Serotonina/metabolismo
Sesquiterpenos/farmacologia
[Mh] Termos MeSH secundário: Animais
Comportamento Animal/efeitos dos fármacos
Feminino
Nociceptividade/efeitos dos fármacos
Ratos
Ratos Wistar
Antagonistas da Serotonina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Indenes); 0 (Receptor, Serotonin, 5-HT1B); 0 (Receptor, Serotonin, 5-HT1D); 0 (Serotonin Antagonists); 0 (Sesquiterpenes); 112692-38-3 (Receptor, Serotonin, 5-HT1A); 1HG84L3525 (Formaldehyde); 34NDB285PM (valerenic acid); PR834Q503T (Ergotamine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170308
[Lr] Data última revisão:
170308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160413
[St] Status:MEDLINE


  4 / 1861 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26995706
[Au] Autor:Donnet A; Braunstein D; Pradel V; Sciortino V; Allaria-Lapierre V; Micallef J; Lanteri-Minet M
[Ad] Endereço:Centre d'évaluation et de traitement de la douleur, Hôpital Timone, Pôle Neurosciences Cliniques, Hôpital de la Timone, Marseille, France.
[Ti] Título:Ergot Use and Overuse: A Pharmacoepidemiology Retrospective Cohort Study.
[So] Source:Headache;56(3):547-54, 2016 Mar.
[Is] ISSN:1526-4610
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The objective of this study was to estimate and to characterize the actual patterns of ergot use and overuse in France using a drug reimbursement database. METHODS: We included all people covered by the French General Health Insurance System (GHIS) from the Provence-Alpes-Côte-d'Azur (PACA) and Corsica administrative areas who had at least one prescription of ergot between May 2010 and December 2011. All prescriptions of ergots, migraine prophylactic treatment, and psychotropic medications were extracted from the GHIS database. We defined occasional ergot users (<3 months of prescription) and regular ergot users (>3 months of prescription). Among regular ergot users, we identified overusers and nonoverusers. RESULTS: We included 4358 patients who had at least one prescription of ergots (oral ergotamine tartrate, dihydroergotamine mesilate nasal spray, intravenous dihydroergotamine mesilate). Among ergot overusers, a large majority of patients had ergotamine tartrate overuse. The proportion of ergotamine tartrate overusers is maximum after 55 years. Compared with regular users, overusers use more frequently a prophylactic treatment (93/165 [56.4%] versus 398/1057, OR = 2.15, P < .001), antidepressants (72/165 [43.6%] versus 326/1057 [30.8%] OR = 1.79, P < .001), benzodiazepines (111/165 [67.3%] versus 613/1057 [58.0%], OR = 1.50, P < .001), weak opioids (95/165 [57.6%] versus 463/1057 [43.8], OR = 1.77, P < .001) and strong opioids (13/165 [7.9%] versus 24/1057 [2.3%], OR = 3.86, P < .001). The coexistence of ergot consumption and triptan overuse, and the possibility of both triptan and ergot overuse was described; triptan overusers were more described in ergotamine overusers than in nonoverusers. CONCLUSIONS: This work outlines a high prevalence of ergotamine tartrate overuse (11.1%). As ergotamine tartrate users are mostly aged more than 55 years, an evaluation of ergotamine cardiovascular risk profile is necessary in the elderly population.
[Mh] Termos MeSH primário: Analgésicos/uso terapêutico
Ergotamina/uso terapêutico
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Estudos de Coortes
Feminino
França/epidemiologia
Seres Humanos
Masculino
Meia-Idade
Transtornos de Enxaqueca/tratamento farmacológico
Farmacoepidemiologia
Prevalência
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); PR834Q503T (Ergotamine)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170110
[Lr] Data última revisão:
170110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160321
[St] Status:MEDLINE
[do] DOI:10.1111/head.12776


  5 / 1861 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26875114
[Au] Autor:Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX
[Ad] Endereço:Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland; Heffter Research Center Zurich, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zuri
[Ti] Título:Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
[So] Source:Eur Neuropsychopharmacol;26(4):756-66, 2016 Apr.
[Is] ISSN:1873-7862
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The mixed serotonin (5-HT) 1A/2A/2B/2C/6/7 receptor agonist psilocybin dose-dependently induces an altered state of consciousness (ASC) that is characterized by changes in sensory perception, mood, thought, and the sense of self. The psychological effects of psilocybin are primarily mediated by 5-HT2A receptor activation. However, accumulating evidence suggests that 5-HT1A or an interaction between 5-HT1A and 5-HT2A receptors may contribute to the overall effects of psilocybin. Therefore, we used a double-blind, counterbalanced, within-subject design to investigate the modulatory effects of the partial 5-HT1A agonist buspirone (20mg p.o.) and the non-hallucinogenic 5-HT2A/1A agonist ergotamine (3mg p.o.) on psilocybin-induced (170 µg/kg p.o.) psychological effects in two groups (n=19, n=17) of healthy human subjects. Psychological effects were assessed using the Altered State of Consciousness (5D-ASC) rating scale. Buspirone significantly reduced the 5D-ASC main scale score for Visionary Restructuralization (VR) (p<0.001), which was mostly driven by a reduction of the VR item cluster scores for elementary and complex visual hallucinations. Further, buspirone also reduced the main scale score for Oceanic Boundlessness (OB) including derealisation and depersonalisation phenomena at a trend level (p=0.062), whereas ergotamine did not show any effects on the psilocybin-induced 5D-ASC main scale scores. The present finding demonstrates that buspirone exerts inhibitory effects on psilocybin-induced effects, presumably via 5-HT1A receptor activation, an interaction between 5-HT1A and 5-HT2A receptors, or both. The data suggest that the modulation of 5-HT1A receptor activity may be a useful target in the treatment of visual hallucinations in different psychiatric and neurological diseases.
[Mh] Termos MeSH primário: Buspirona/farmacologia
Transtornos da Consciência/induzido quimicamente
Ergotamina/farmacologia
Alucinógenos/farmacologia
Voluntários Saudáveis/psicologia
Psilocibina/farmacologia
Agonistas de Receptores de Serotonina/farmacologia
[Mh] Termos MeSH secundário: Escala de Avaliação Comportamental
Transtornos da Consciência/psicologia
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Psilocibina/antagonistas & inibidores
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Hallucinogens); 0 (Serotonin Receptor Agonists); 2RV7212BP0 (Psilocybin); PR834Q503T (Ergotamine); TK65WKS8HL (Buspirone)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170503
[Lr] Data última revisão:
170503
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160215
[St] Status:MEDLINE


  6 / 1861 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26608012
[Au] Autor:Voilliot D; Girerd N; Magne J
[Ad] Endereço:Centre Hospitalier Universitaire de Nancy, Service de Cardiologie, Institut Lorrain du CÅ“ur et des Vaisseaux, VandÅ“uvre-lès-Nancy, France; IADI, INSERM U947, University of Lorraine, Nancy, France. Electronic address: d.voilliot@chu-nancy.fr.
[Ti] Título:Right heart/pulmonary circulation unit assessment during exercise, a need for a global view of the loop.
[So] Source:Int J Cardiol;203:1147-8, 2016 Jan 15.
[Is] ISSN:1874-1754
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Ecocardiografia Doppler em Cores/métodos
Ecocardiografia sob Estresse/métodos
Ergotamina/efeitos adversos
Insuficiência da Valva Mitral/induzido quimicamente
Função Ventricular Esquerda/fisiologia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
PR834Q503T (Ergotamine)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:151222
[Lr] Data última revisão:
151222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151127
[St] Status:MEDLINE


  7 / 1861 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26574240
[Au] Autor:Maréchaux S; Tribouilloy C; Ennezat PV
[Ad] Endereço:Groupement des Hôpitaux de l'Institut Catholique de Lille, Faculté libre de médecine, Université Catholique de Lille, Université Lille Nord de France, Lille, France. Electronic address: sylvestre.marechaux@yahoo.fr.
[Ti] Título:Echocardiography and cardiac catheterism as complementary tools for the assessment of pulmonary circulation during exercise.
[So] Source:Int J Cardiol;203:1149-50, 2016 Jan 15.
[Is] ISSN:1874-1754
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Ecocardiografia Doppler em Cores/métodos
Ecocardiografia sob Estresse/métodos
Ergotamina/efeitos adversos
Insuficiência da Valva Mitral/induzido quimicamente
Função Ventricular Esquerda/fisiologia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
PR834Q503T (Ergotamine)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:151222
[Lr] Data última revisão:
151222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151118
[St] Status:MEDLINE


  8 / 1861 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25099482
[Au] Autor:Ozpelit E; Ozpelit ME; Akdeniz B; Göldeli Ö
[Ad] Endereço:1Department of Cardiology, School of Medicine, Dokuz Eylul University, Izmir, Turkey; and 2Department of Cardiology, Medical Park Hospital, School of Medicine, Izmir University, Izmir, Turkey.
[Ti] Título:Ergotamine-Induced Takotsubo Cardiomyopathy.
[So] Source:Am J Ther;23(2):e597-600, 2016 Mar-Apr.
[Is] ISSN:1536-3686
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Takotsubo cardiomyopathy (TC) is a recently increasing diagnosed disease showed by transient apical or mid-apical left ventricular dysfunction. It is known as a disease of postmenopausal women, which is usually triggered by emotional or physical stress. Although the trigger is mostly endogenous, some drugs have also been reported as the cause. Published case reports of TC associated with drug usage consist of sympathomimetic drugs, inotropic agents, thyroid hormone, cocaine, and 5-fluorouracil. We present an unusual case of TC in which the possible trigger is ergotamine toxicity.
[Mh] Termos MeSH primário: Ergotamina/efeitos adversos
Transtornos de Enxaqueca/tratamento farmacológico
Cardiomiopatia de Takotsubo/induzido quimicamente
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
PR834Q503T (Ergotamine)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140808
[St] Status:MEDLINE
[do] DOI:10.1097/MJT.0000000000000030


  9 / 1861 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25828325
[Au] Autor:Maréchaux S; Brahim YB; Ennezat PV; Delelis F; Tribouilloy C
[Ad] Endereço:Université Lille Nord de France, GCS-Groupement des Hôpitaux de l'Institut Catholique de Lille, Faculté Libre de Médecine, Cardiology Department, Université Catholique de Lille, 59000 Lille, France; INSERM U 1088, Université de Picardie, Amiens, France. Electronic address: sylvestre.marechaux@yahoo.
[Ti] Título:Dynamic drug-induced organic mitral regurgitation during exercise echocardiography following chronic exposure to ergotamine.
[So] Source:Int J Cardiol;187:106-8, 2015.
[Is] ISSN:1874-1754
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Ecocardiografia Doppler em Cores/métodos
Ecocardiografia sob Estresse/métodos
Ergotamina/efeitos adversos
Insuficiência da Valva Mitral/induzido quimicamente
Função Ventricular Esquerda/fisiologia
[Mh] Termos MeSH secundário: Idoso
Diagnóstico Diferencial
Feminino
Seres Humanos
Insuficiência da Valva Mitral/diagnóstico por imagem
Insuficiência da Valva Mitral/fisiopatologia
Agonistas de Receptores de Serotonina/efeitos adversos
[Pt] Tipo de publicação:CASE REPORTS; LETTER; VIDEO-AUDIO MEDIA
[Nm] Nome de substância:
0 (Serotonin Receptor Agonists); PR834Q503T (Ergotamine)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150402
[St] Status:MEDLINE


  10 / 1861 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25712664
[Au] Autor:Zajdel P; Bednarski M; Sapa J; Nowak G
[Ad] Endereço:Department of Medicinal Chemistry, Jagiellonian University Medical College, Kraków, Poland. Electronic address: pawel.zajdel@uj.edu.pl.
[Ti] Título:Ergotamine and nicergoline - facts and myths.
[So] Source:Pharmacol Rep;67(2):360-3, 2015 Apr.
[Is] ISSN:1734-1140
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Ergotamine, being a representative of naturally occurring ergoline alkaloids, derived from d-lysergic acid, and nicergoline, a d-lumilysergic acid derivative belonging to semi-synthetic ergot-derived alkaloids, display diversified affinity for adrenergic, serotoninergic, and dopamine receptors. Although introduction of triptans marginalized use of ergotamine, nicergoline is used in cerebral metabolic-vascular disorders, and dementia. Additionally, nicergoline exhibits a safety profile comparable to that of placebo, and none of the reviewed studies reported any incidence of fibrosis or ergotism with nicergoline treatment. In line with the recent data, activation of 5-HT2B receptor by ergot derivatives i.e. ergotamine, methysergide, pergolide, and carbegoline is involved in pathogenesis of drug-induced valvulopathy. In contrary structurally related drugs - lisuride and terguride do not increase the risk of valvular heart disease. It seems, that more detailed mechanistic studies on nicergoline and ergotamine might be beneficial for determining structural requirements related to activation of G-protein as well as alternative signal transduction pathways e.g. ß-arrestins or different kinases, and responsible for drug liabilities.
[Mh] Termos MeSH primário: Ergotamina/efeitos adversos
Doenças das Valvas Cardíacas/induzido quimicamente
Nicergolina/efeitos adversos
[Mh] Termos MeSH secundário: Ergotamina/farmacologia
Ergotamina/uso terapêutico
Seres Humanos
Nicergolina/farmacologia
Nicergolina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
JCV8365FWN (Nicergoline); PR834Q503T (Ergotamine)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:150225
[Lr] Data última revisão:
150225
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150226
[St] Status:MEDLINE



página 1 de 187 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde